Insider buying last 90 days
No open-market insider purchases were filed for MMSI in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
This week's news centers on Merit Medical's WRAPSODY Cell-Impermeable Endoprosthesis, with multiple releases of real-world data from the WRAP Global registry's AVF cohort. Results show a six-month target lesion primary patency rate of 92.7% and an access circuit primary patency rate of 76.7%, covering 237 patients across 31 sites, with commentary noting these compare favorably to the WAVE pivotal trial data. This follows the Q3 2026 report on 29 October, when Merit Medical posted revenue of $416 million, up 8% year-over-year, with EPS of $1.12 against an estimate of $1.04, though the stock reacted -6.5% to that release.
MMSI closed at $88.42, up 1.4%, sitting above both its 50-day average of $88.23 and its 200-day average of $77.10. The GekkoIndex reads 59, placing the stock in the Neutral zone, down 5.8 over five days. Gekko Fair Value stands at $107.09, leaving price 17.4% below that mark. Over the past six months the stock has returned 46.6%, though the three-month return is -3%.
The next earnings date falls on 23 February 2027, 105 days out, placing it beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality skews unfavorable, with the next 20 trading days averaging -1.8% over 5 years, rising in 2 of them. Analyst consensus from 9 firms includes 7 buy and 2 hold ratings, with a consensus target of 107 and consensus upside of 21%.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Merit Medical Systems scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
Averages disagree
Close $86.63 sits between the 50-day ($88.02) and 200-day ($77.22) averages, or the averages disagree.
See the chart61.1, Accumulation
Reading 61.1 is in the Accumulation zone.
See the GekkoIndex14.5% below
Price is 14.5% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings0.0% on average
From this point in the calendar, the next 20 trading days averaged 0% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Merit Medical Systems closed at $86.63 on Nov 13, 2026, −1.7% over the past year, inside a 52-week range of $59.74 to $94.85.
Use the left and right arrow keys to read daily values.
Put MMSI on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Merit Medical Systems designs and builds disposable devices used by clinicians during diagnostic, therapeutic and interventional work, with a strong presence in cardiology, radiology, oncology, critical care and endoscopy. It has built a wide catalog of tools meant to support treatment of blood vessels, organs and heart conditions, covering everything from angiography to hemostasis.
Operations are split between a Cardiovascular division and an Endoscopy division. Product lines take in access and monitoring devices, electrophysiology and rhythm-management equipment, procedure trays, coated tubing, sensor parts used in microelectromechanical systems, stents for the airway, dilation balloons and various gastroenterology and bronchoscopy kits. Hospitals, physicians, nurses and technicians across different treatment settings make up its customer base, and goods move through an in-house sales team along with outside distributors, OEM agreements and companies that assemble custom procedure trays, serving buyers both at home and abroad.
The company traces back to 1987 and runs its main offices out of South Jordan, Utah. Its stock trades on the NASDAQ under the ticker MMSI.
Merit Medical Systems’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.1, in the Accumulation zone, up 1.4 points over five sessions.
Up 1.4 points over five sessions, from the Neutral zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 42 | −0.3% | −0.2% | ||
| Accumulation (current zone) | 225 | +0.5% | +1.8% | ||
| Neutral | 396 | 0.0% | +0.2% | ||
| Distribution | 30 | −0.1% | −0.9% | ||
| Selling | 9 | Too few readings yet | |||
Average MMSI share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Merit Medical Systems trades 14.5% below Gekko Fair Value of $101.38, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Merit Medical Systems shares are worth, recalculated every trading day.
$101.38
Gekko Fair Value, Nov 14, 2026
14.5% Undervalued
At the end of Aug 2026 the price was 18.3% below the estimate.
No open-market insider purchases were filed for Merit Medical Systems, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for MMSI in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in MMSI were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Merit Medical Systems reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 23, 2027
Expected after the close, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $1.12 est $1.04 | $416.2M est $410.6M | −6.5% |
| Jul 30, 2026 | $1.09 est $0.85 | $418.8M est $405.2M | +5.2% |
| Apr 30, 2026 | $0.94 est $0.83 | $381.9M est $377.6M | −4.4% |
| Feb 24, 2026 | $1.04 est $0.95 | $393.9M est $389.9M | −2.9% |
| Oct 30, 2025 | $0.92 est $0.82 | $384.2M est $388.3M | +7.6% |
| Jul 30, 2025 | $1.01 est $0.86 | $382.5M est $371.5M | +2.4% |
| Apr 24, 2025 | $0.86 est $0.75 | $355.4M est $352.5M | +0.9% |
| Feb 25, 2025 | $0.93 est $0.83 | $355.2M est $351.5M | −3.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Merit Medical Systems is $107.00, +23.5% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 30 | Robert W. Baird | $107 | +23.5% |
| Oct 30 | Canaccord Genuity | $121 | +39.7% |
| Oct 30 | Piper Sandler | $108 | +24.7% |
| Oct 30 | Barrington | $116 | +33.9% |
| Oct 30 | BTIG | $110 | +27.0% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Merit Medical Systems averaged 0.0% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.1% | 4 of 5 |
| Next 10 trading days | −1.4% | 3 of 5 |
| Next 15 trading days | −1.2% | 2 of 5 |
| Next 20 trading days | 0.0% | 3 of 5 |
| Next 30 trading days | −0.3% | 3 of 5 |
For scale, MMSI’s typical 20-trading-day move in either direction is about 5.5%.
Merit Medical Systems’s market cap is $5.19B, with a P/E ratio of 32.5 and revenue of $1.61B over the last twelve months.
Coverage of Merit Medical Systems this week reads positive: 3 positive, 3 neutral and 1 negative headlines.
Merit Medical Systems’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Merit Medical Systems’s market cap is $5.19B at the Nov 13, 2026 close of $86.63, with 59.92M shares outstanding. The shares trade on a P/E ratio of 32.5.
The consensus analyst 12-month price target for Merit Medical Systems is $107.00, +23.5% from the last close. Of the 9 firms that rated the stock in the last 90 days, 7 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Merit Medical Systems is undervalued: the Nov 13, 2026 close of $86.63 is 14.5% below Gekko Fair Value of $101.38. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Merit Medical Systems is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of $1.11 per share on revenue of $422.8M. Merit Medical Systems beat the earnings estimate in 8 of its last 8 reports, moving 4.1% on average across the report.
Merit Medical Systems’s 52-week high is $94.85 and its 52-week low is $59.74; it closed at $86.63 on Nov 13, 2026, −1.7% over the past year. Over the last five years the shares peaked at $111.45 on Jan 31, 2025.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.